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Abstract
Introduction: Although the heritability of sporadic Alzheimer’s disease (AD) is estimated to be 60–80%, addressing
the genetic contribution to AD risk still remains elusive. More specifically, it remains unclear whether genetic
variants are able to affect neurodegenerative brain features that can be addressed by in vivo imaging techniques.
Methods: Targeted sequencing analysis of the coding and UTR regions of 132 AD susceptibility genes was
performed. Neuroimaging data using 11C-Pittsburgh Compound B positron emission tomography (PET), 18F-
fluorodeoxyglucose PET, and MRI that are available from the KBASE (Korean Brain Aging Study for Early Diagnosis
and Prediction of Alzheimer’s disease) cohort were acquired. A total of 557 participants consisted of 336 cognitively
normal (CN) adults, 137 mild cognitive impairment (MCI), and 84 AD dementia (ADD) groups.
Results: We called 5391 high-quality single nucleotide variants (SNVs) on AD susceptibility genes and selected
significant associations between variants and five in vivo AD pathologies: (1) amyloid β (Aβ) deposition, (2) AD-
signature region cerebral glucose metabolism (AD-Cm), (3) posterior cingulate cortex (PCC) cerebral glucose
metabolism (PCC-Cm), (4) AD-signature region cortical thickness (AD-Ct), and (5) hippocampal volume (Hv). The
association analysis for common variants (allele frequency (AF) > 0.05) yielded several novel loci associated with Aβ
deposition (PIWIL1-rs10848087), AD-Cm (NME8-rs2722372 and PSEN2-rs75733498), AD-Ct (PSEN1-rs7523) and, Hv
(CASS4-rs3746625). Meanwhile, in a gene-based analysis for rare variants (AF < 0.05), cases carrying rare variants in
LPL, FERMT2, NFAT5, DSG2, and ITPR1 displayed associations with the neuroimaging features. Exploratory voxel-based brain
morphometry between the variant carriers and non-carriers was performed subsequently. Finally, we document a strong
association of previously reported APOE variants with the in vivo AD pathologies and demonstrate that the variants exert
a causal effect on AD susceptibility via neuroimaging features.
Conclusions: This study provides novel associations of genetic factors to Aβ accumulation and AD-related
neurodegeneration to influence AD susceptibility.
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Background
Alzheimer’s disease (AD), the most common cause of
dementia, is a neurodegenerative disease with high herit-
ability estimated to be 60–80% [1, 2]. Previous genetic
studies have elucidated causative rare variants contribut-
ing to familial AD that commonly occurs before the age
of 65 (early onset). These variants are found in genes re-
lated to amyloid beta (Aβ) synthesis, such as APP (amyl-
oid precursor protein), PSEN1 (presenilin 1), and PSEN2
(presenilin 2) [3]. However, as early-onset familial AD
accounts for < 5% of AD cases [2, 3], unraveling the
complex genetic contributions to sporadic AD cases,
which represents the majority of AD cases that occur
after age 65 (late onset), is important. To date, apolipo-
protein E (APOE) ε4 allele (APOE4) is the strongest gen-
etic factor of sporadic AD [4], which confers a 3- to 15-
fold increased risk of AD [5]. Recent large-scale
genome-wide association studies (GWAS) have identi-
fied novel common variants of AD in loci involved in
amyloid synthesis, nervous system development, synaptic
transmission, and inflammation pathways [4, 6–9].
Nevertheless, APOE4 and several other common variants
identified by previous GWAS explain a modest fraction
of AD heritability [4], and addressing the remainder still
remains as a challenge.
Most of the previous GWAS relied on phenotypes de-
fined by clinical diagnosis of AD dementia (ADD) [8] and
not by AD pathology or its surrogate biomarkers. There-
fore, it remains unclear whether previously reported genes
exert associations through modulating in vivo AD path-
ologies. Also, applying next-generation sequencing (NGS)
technologies increases the possibility of detecting rare var-
iants with large effect on diseases, which may help to ex-
plain the missing heritability [2, 10]. Although recent
efforts to aggressively integrate genome-wide effects of
common and rare variants has substantially improved our
understanding of AD genetics [11, 12], how individual var-
iants function to confer such effects still requires further
investigation. A number of previous studies investigated
genetic association with in vivo AD pathologies using AD
biomarkers, but none has utilized multiple in vivo AD
pathology features and integrated them with common and
rare genetic variants [13–18].
Although genome-wide approaches enable unbiased
screening of novel variants, we chose to perform a tar-
geted sequencing (TS) approach as it provided the fol-
lowing advantages. First, overarching hypothesis of the
study assumes that there are quantifiable contributions
of imaging biomarkers on the known genetic signals for
LOAD, thereby aiming to provide clues of variant func-
tions. Therefore, we decided to focus our analyses on
the selected 132 genes with previous associations with
LOAD. Second, compared to genome-wide approaches,
the number of data points in TS is substantially smaller
and allows reduced statistical penalty. Lastly, TS reduces
sequencing cost and allows easier data handling.
Based on an imaging genetics approach, this work
aimed to identify common and rare genetic variants
closely associated with cerebral Aβ deposition and AD-
type neurodegeneration by conducting a TS analysis of
132 AD-related genes in 557 deep-phenotyped partici-
pants with multi-modal brain imaging information in-
cluding [11C] Pittsburgh Compound B (PiB)-positron
emission tomography (PET), [18F] fluorodeoxyglucose
(FDG)-PET, and magnetic resonance imaging (MRI).
Our multivariable analysis approach provides a more ac-
curate model for AD susceptibility by comparing with
biomarkers for in vivo AD pathology.
Materials and methods
Participants
We evaluated 557 participants who were recruited by the
Korean Brain Aging Study for the Early Diagnosis and
Prediction of Alzheimer’s disease (KBASE), a prospective
cohort study initiated in 2014 (Supplementary Table S1)
[13]. Participants consisted of 274 cognitively normal
(CN) older adults (CN-old, age ≥ 55), 62 CN young and
middle-aged adult (CN-ym, age < 55), 137 individuals with
mild cognitive impairment (MCI), and 84 patients with
ADD. Details on the recruitment and inclusion/exclusion
criteria are described in the Supplementary Methods.
Evaluation of in vivo AD pathologies
All participants underwent comprehensive clinical and
neuropsychological evaluations and multi-modal brain
imaging (including [11C]PiB-PET, [18F]FDG-PET, and
MRI). Blood was sampled for DNA extraction. APOE
genotyping was conducted as previously described [18].
More detailed information on the standardized assess-
ment used in the KBASE cohort is described in a previ-
ous report [13]. For surrogate markers of in vivo
cerebral Aβ deposition, we quantified the standardized
uptake value ratio (SUVR) of global [11C] PiB retention
level in the cortical region-of-interests (ROIs). [18F]FDG-
PET was used to measure cerebral glucose metabolism
in the AD-signature regions (AD-Cm) and posterior cin-
gulate cortex (PCC-cm), which can capture early re-
gional metabolic and functional deficits related to AD
processes [14, 15]. T1 MRI was used to evaluate cortical
thickness in the AD-signature regions (AD-Ct) [19] and
intracranial volume-adjusted hippocampal volume (Hv)
[16] based on previous studies. Details of acquisition and
preprocessing of [11C]PiB-PET, [18F]FDG-PET, and MRI
and the definition of each AD imaging biomarker are
provided in the Supplementary Methods and Supple-
mentary Table S2.
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AD gene panel, sequencing, and variant calling
The 132 genes were selected according to one of the fol-
lowing criteria: (1) genes from previous AD GWAS (n =
32) [6–9], (2) genes with mutations reported to be
causative for familial AD in the OMIM database (n =
19), (3) genes with biological relevance in AD in the
KEGG pathway (hsa05010) (n = 53), or (4) manually se-
lected genes with potential relevance in AD (n = 28)
(Supplementary Table S3). The AD gene panel was de-
signed using the Ion AmpliSeq Designer (http://ampli-
seq.com) and contained 5049 amplicons with sizes
ranging from 125 to 275 bp. The target regions included
UTR and coding exons with 10 bases of padding se-
quences, totaling 1.46Mb and covering 96% of the tar-
geted intervals. AD-targeted panel sequencing was
performed with an Ion Proton sequencer (Supplemen-
tary Methods, Supplementary Fig. S1 and Supplementary
Table S4). The reads were aligned to hg19 and SNVs
were called using Torrent Suite v3.4.2. Variants with <
20× coverage, located in homopolymer repeats, or cov-
ered < 90% of the samples were excluded. After applying
the variant filtering criteria established in our pilot ex-
periments (Supplementary Methods and Supplementary
Fig. S1), 5391 variants remained.
Association tests
Both continuous and categorical variables indicating
in vivo AD pathologies were normalized and used as
dependent variables to identify common variants (allele
frequency (AF) > 0.05) associated with bioimaging
markers (Supplementary Methods and Supplementary
Table S2). Age, sex, and the number of APOE4 alleles
were used as covariates. Significant associations were de-
fined at an uncorrected P < 0.001, following the previous
studies [20–22], and the Benjamini and Hochberg
method was used for multiple test correction for APOE
variant association tests (Supplementary Table S5).
Among the rare variants (AF < 0.05), loss-of-function
(LoF) variants and missense variants with strong evolu-
tionary conservation were selected for gene-based asso-
ciation analyses. R (version 3.5.1) was used to conduct
Fisher’s exact test with the five binominal neuroimaging
traits (Supplementary Table S2) and cognitive impair-
ment, and rare variant enrichment across each gene was
adjusted by length. For APOE variants, variants with
AF > 0.1 were selected and tested for association, after
adjusting for age and sex. For conditional analysis, a
quantitative imaging trait was used as a covariate in an
association test of APOE variants and AD susceptibility.
Voxel-based analysis of multi-modal brain imaging
To identify regional PiB uptake differences, Statistical
Parametric Mapping 12 (SPM12; http://www.fil.ion.ucl.
ac.uk/spm) was used for the exploratory voxel-based
analysis of [11C]PiB-PET. Similarly, voxel-based analyses
of [18F]FDG-PET and T1 MRI were performed to
visualize the differences of regional cerebral glucose me-
tabolism or gray matter (GM) density by the presence of
variants associated with AD-Cm, PCC-Cm, AD-Ct, or
Hv. Additional details of the voxel-wise analysis of com-
mon variants and genes with rare variants are provided
in the Supplementary Methods.
Results
Establishment of the AD panel, quality assessment, and
variant calling strategy
The overall study design and documented in vivo path-
ology biomarkers are represented in Fig. 1a, b. The clin-
ical and demographic characteristics of the 557
participants are described in Supplementary Table S1.
The mean age of the participants is 67.4 years, and
57.8% are women. The frequency of the APOE4 allele in
each diagnostic group indicated a strong disease associ-
ation (i.e., 9.3% and 35.7% for CN-old and dementia
groups, respectively). The mean coverage depth of the
AD target sequencing runs was 436.8×, and 97.8% of the
targeted bases were covered more than 20×, ensuring
high variant sensitivity (Supplementary Table S4).
We developed an in-house SNV calling method for
ion proton sequencing data. Prior to data production,
we optimized the variant calling pipeline through a
series of pilot experiments and demonstrated 92.4% sen-
sitivity and 93.5% specificity (Supplementary Fig. S1). To
further validate the quality of the 5391 called variants,
principal component analysis (PCA) of the KBASE co-
hort was performed with individuals from the 1000 Ge-
nomes Project, which showed that our cohort co-
clustered with the East Asian group (Fig. 1c). A strong
correlation of AFs between our cohort and 1000 Ge-
nomes East Asian was observed (Pearson’s r = 0.99 [95%
CI, 0.989–0.991]). The majority of the variants (79.2%)
are rare (AF < 0.05), and 45.2% were singletons (seen
once in our cohort; Fig. 1d). The majority of the variants
(88.9%) with an AF > 0.001 are already listed in the 1000
Genomes, The Genome Aggregation Database (gnomAD),
and the Korean Variant Archive (KOVA) [23–25]. The
variants are composed of 31.5% UTR, 1.9% intergenic,
33.7% intronic, and 32.9% coding region locations (Fig. 1e).
Each individual carried an average of 369.0 heterozygous
variants, 295.4 homozygous variants, and 4.4 singletons.
The mean ratio of missense-to-silent variants was 0.44,
and the mean ratio of transition-to-transversion variants
was 2.83 per individual, comparable to other large-scale
genome data sets [26].
Common variant association test
Tests that evaluated the association between common
variants and Aβ deposition, AD-Cm, PCC-Cm, AD-Ct,
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and Hv revealed seven loci with strong associations, of
which six are novel (Table 1). The CN-ym group was ex-
cluded from the test, as this group was entirely negative
for the in vivo AD imaging biomarkers regardless of
genotype.
Variants in GORASP1 (rs28362644; odds ratio [OR]
0.46 [0.29–0.72]; P = 7.0 × 10−4), MADD (rs2290149;
OR 2.74 [1.61–4.68]; P = 2.0 × 10−4), and PIWIL1
(rs10848087; regression coefficient [β] 0.14 [0.06–
0.22]; P = 5.1 × 10−4) were significantly associated with
Aβ deposition (Table 1; Fig. 2a; Supplementary Fig.
S2a). Comparison with voxel-based imaging data (P <
0.01, k = 1497) revealed that carriers of MADD-
rs2290149 displayed greater Aβ deposition mainly in
the bilateral, lateral, and medial frontal cortices; cin-
gulate; precuneus; and lateral temporal and inferior
parietal regions. PIWIL1-rs10848087 non-carriers
showed diffuse Aβ accumulation in the bilateral cere-
bral cortices including the frontal, temporal, parietal,
occipital lobes and basal ganglia (Fig. 2a). Three SNVs
near GORASP1 were identified, located in the same
linkage disequilibrium (LD) block (R2 = 0.98; D′ =
0.99), and the most robust SNP, rs28362644, was used
for imaging analysis (Table 1). GORASP1-rs28362644
carriers showed less Aβ deposition in the posterior
hippocampal and parahippocampal regions, as well as
retrosplenial and precuneus regions at a more lenient
threshold compared to non-carriers (P < 0.05, k =
5058; Supplementary Fig. S2a).
Two novel significant associations with AD-Cm were
observed: PSEN2-rs75733498 (OR 0.39 [0.23–0.63]; P =
1.8 × 10−4) and NME8-rs2722372 (β − 0.04 [− 0.06 to −
0.018]; P = 7.6 × 10−4) (Table 1; Fig. 2b; Supplementary
Fig. S2b). Subsequent voxel-based FDG-PET analysis re-
vealed that PSEN2-rs75733498 non-carriers had reduced
glucose metabolism levels in the bilateral fronto-
temporo-parietal cortices (P < 0.01, k = 1497; Fig. 2b). On
the other hand, NME8-rs2722372 carriers displayed dif-
fuse cerebral glucose hypometabolism in the bilateral
fronto-temporo-parietal cortices and subcortical struc-
tures, such as the thalamus and basal ganglia (Fig. 2b).
An association between AD-Cm and NME8-rs2722372
in the PCC was also observed.
PSEN1-rs7523 (OR 0.39 [0.25–0.60]; P = 1.7 × 10−5)
and PIWIL1-rs10848087 (β − 0.07 [− 0.11 to − 0.03]; P =
2.9 × 10−4) were associated with AD-Ct (Table 1; Fig. 2c;
Supplementary Fig. S2c). Exploratory voxel-based ana-
lysis of T1 MRI demonstrated that PSEN1-rs7523 non-
carriers showed reduced cortical thicknesses as com-
pared to carriers in the inferior frontal, orbitofrontal,
and basal ganglia (P = 2.5 × 10−5, k = 1497; Fig. 2d).
Finally, CASS4-rs3746625 (β 0.54 [0.26–0.82]; P =
1.7 × 10−4) and PIWIL1-rs10848087 (β − 0.40 [− 0.61 to
− 0.19]; P = 2.3 × 10−4) strongly correlated with Hv
(Table 1; Fig. 2d; Supplementary Fig. S2c). There are also
three other significant SNVs in CASS4 that are located
in the same LD block with rs3746625 (R2 = 1.00; D′ =
1.00). Brain images showed that GM atrophy was
Fig. 1 Study design and variant profile of the cohort. a Flowchart of the study design. b Phenotyping strategies of in vivo AD pathology. c
Principal component analysis (PCA) of the KBASE cohort with individuals from the 1000 Genomes Project individuals across different populations.
d Distribution of variants in the KBASE cohort by population frequency. e Distribution of variants by genetic regions
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reduced in rs3746625 carriers than non-carriers, particu-
larly in the bilateral medial temporal regions including
the hippocampi (P < 0.01, k = 1497; Fig. 2d). To elucidate
the functional implication of the CASS4 and PIWIL1
variants in the brain, ChIP-seq data from the ENCODE
were utilized [28]. Notably, H3K27me3 signals, which
mark heterochromatin, encompass the variants specific-
ally in the hippocampus, but not in other parts of the
brain or other organs, consistent with the results of
voxel-based analysis of MRI (Supplementary Fig. S3).
The cumulative effect of common variants associated
with the imaging biomarkers was evaluated by correlat-
ing AD risk score, defined as the weighted sum of the ef-
fect sizes of common variants associated with imaging
features and the proportion of individuals with cognitive
impairment (i.e., MCI or ADD; Supplementary Fig. S4).
Common SNVs associated with each imaging biomarker
(P < 0.05) explained 27–58% of cognitive impairment
and 76% when used in combination.
Effect of APOE variants
The APOE4 allele possesses the strongest association
with AD susceptibility [8], but comprehensive analysis of
its impact on structural and functional changes in a large
number of aging brains remains understudied. In
addition, our study design allowed association
assessment of other APOE variants. Therefore, we
sought to identify association between APOE common
variants and the imaging features. Rare variants were not
detected. We tested three common variants with an
AF > 0.1. Two variants, rs429358 and rs769449, are lo-
cated in the same LD block (R2 = 0.73, D′ = 0.95; Fig. 3a)
and are strongly correlated with all five imaging traits
(Table 2; Fig. 3b). An additional variant (rs405509) lo-
cated in the promoter is in weak LD with rs429358
(R2 = 0.05, D′ = 1.00) and rs769449 (R2 = 0.06, D′ = 0.96;
Fig. 3a). rs405509 possessed minimal association with
the brain features (Table 2), with the association specif-
ically residing in the 3′-portion of the gene.
Conditional analysis was performed to test if the in-
fluence of these APOE variants on neuroimaging fea-
tures is causal to ADD risk (Table 2). Adjusting for
each brain imaging feature effectively reduced the as-
sociation between the two SNVs (rs429358 and
rs769449) and AD susceptibility by approximately
105- to 108-fold in P values. This result suggests that
the APOE variants modulate neuroimaging features
that contributes to AD susceptibility. Conversely, the
significance of another variant (rs405509) did not
change after conditioning, indicating that brain im-
aging features are independent of its association with
AD susceptibility.
Table 1 List of common variants that significantly associated with brain imaging features (P < 1.0 × 10−3)
AD imaging biomarker Data type Chr:position (hg19) dbSNP ID Genea PFb Previously reported P
I. Cerebral amyloid-β accumulation measured by PiB-PET
Aβ deposition Bin.c chr3:39138840 rs3732377 GORASP1 0.237 Novel 9.32 × 10−4
chr3:39139776 rs1109643 GORASP1 0.161 Novel 9.79 × 10−4
chr3:39149277 rs28362644 GORASP1 0.162 Novel 7.02 × 10−4
chr11:47345916 rs2290149 MADD 0.082 Novel 2.02 × 10−4
Quant.d chr12:130839165 rs10848087 PIWIL1 0.105 Novel 5.05 × 10−4
II. Glucose metabolism levels measured by FDG-PET
AD-Cm Bin. chr1:227077809 rs75733498 PSEN2 0.083 Novel 1.75 × 10−4
Quant. chr7:37890267 rs2722372 NME8 0.191 Novel 7.63 × 10−4
PCC-Cm Quant. chr7:37890267 rs2722372 NME8 0.191 Novel 5.71 × 10−4
III. Cortical thickness measured by MRI
AD-Ct Bin. chr14:73686944 rs7523 PSEN1 0.161 Novel 1.74 × 10−5
Quant. chr12:130839165 rs10848087 PIWIL1 0.105 Novel 2.94 × 10−4
IV. Hippocampal volume reduction measured by MRI
Hv Quant. chr20:55033476 rs3746623 CASS4 0.945 Novel 1.73 × 10−4
chr20:55033647 rs3746625 CASS4 0.946 Novel 1.73 × 10−4
chr20:55033713 rs3746626 CASS4 0.946 Novel 1.73 × 10−4
chr20:55033856 rs4811697 CASS4 0.946 Known [27] 3.42 × 10−4
Both chr12:130839165 rs10848087 PIWIL1 0.105 Novel 4.24 × 10−4
aThe most closely located gene from each variant
bPopulation frequency in the KBASE cohort
cCategorical variable trait transformed from normalized neuroimaging data by each criterion
dQuantitative normalized neuroimaging variable trait
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Fig. 3 Association of APOE variants with AD imaging biomarkers. a Log10-scaled coverage map of APOE in the KBASE cohort, along with the
gene structure shown with gray boxes indicating exons. Black lines indicate the average coverage depths. On the right, AF of the three APOE
variants in KBASE and major ethnic groups are displayed. b Regression plots for the three variant genotypes and imaging traits after adjusted
with age and sex
Fig. 2 Common variants that are significantly associated with neuroimaging features. For each signal, a circular Manhattan plot, quantile-quantile
(Q-Q) plot, regional plot, regression plot with adjusted trait values, and voxel-based clustering analysis result are shown. a rs10848087 in PIWIL1 with
cerebral Aβ deposition in global brain regions. b rs2722372 in NME8 with AD-Cm. c rs7523 in PSEN1 with AD-Ct. d rs4811697 in CASS4 with Hv
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Gene-level analysis for rare variants
To investigate the associations of rare variants with AD
imaging biomarkers and cognitive impairment, we col-
lected functional rare variants (AF < 0.05, LoF or evolu-
tionary conserved missense variants). A total of eight
genes appeared to be significant at a gene-level analysis
(P < 0.05; Fig. 4; Supplementary Table S6 and Supplemen-
tary Fig. S5). Variants in LPL were detected only in cases
with high Aβ deposition (n = 3, P = 0.03; Fig. 4a). No rare
variants were significantly associated with AD-Cm hypo-
metabolism, but FERMT2 (OR 2.37 [1.07–5.61]; P = 0.02)
and NFAT5 (OR 4.24 [1.15–23.32]; P = 0.02) showed sig-
nificant enrichment for the presence of PCC hypometabo-
lism (Table. S5). DSG2 showed significant enrichment in
controls with normal AD-Ct and Hv (OR 0.17 [0.02–
0.89], P = 0.02, and OR 0.0 [0.00–1.02], P = 0.03; Fig. 4b;
Supplementary Fig. S5a). Interestingly, the observed rare
variants were mainly located in the sites that bind calcium
ions or other proteoglycans, such as N-acetylglucosamine
(Supplementary Fig. S6c). Also, functional variants in
ITPR1 were observed only in controls with normal Hv
(n = 9; Fig 4c). These results demonstrate novel associa-
tions between rare variants and brain features that can be
documented by imaging techniques.
Discussion
We investigated the associations between genetic vari-
ants and various brain features that are accessible via
imaging techniques. We identified a group of variants
that are linked to Aβ deposition, AD-Cm, PCC-cm, AD-
Ct, and Hv (Fig. 1b). Our results bolster the role of
APOE alleles in contributing to AD pathogenesis
susceptibility.
The association analysis of common variants led to the
discovery of seven significant associations with AD brain
imaging biomarkers. Particularly, we observed an associ-
ation between CASS4 common variants and Hv (Table 1).
Previous association studies suggested that CASS4, en-
coding a cytoskeletal protein that provides a physical
connection with the extracellular matrix, contributes to
the risk of ADD [8, 27]. Our observation implies that
the previously reported association between CASS4 and
ADD may be through neurodegeneration of the hippo-
campus via an Aβ-independent pathway. Voxel-wise
analysis of MRI demonstrated a region-specific GM at-
rophy in the bilateral hippocampi and adjacent regions
in CASS4 variant carriers (Fig. 2d). The presence of
hippocampus-specific H3K27me3 signals (Supplemen-
tary Fig. S3a) suggests that these variants are related to a
region-specific epigenetic modification in the hippocam-
pus, although future studies will be necessary to clarify
the function of these CASS4 variants.
PIWIL1 common variants are related to both Aβ de-
position and atrophy in the AD-signature region and the
hippocampus (Table 1 and Supplementary Table S7).
Voxel-wise analysis of PiB-PET consistently revealed
that PIWIL1 variant carriers displayed greater levels of
cerebral Aβ deposition as compared to non-carriers, and
regional GM atrophy mainly in the bilateral temporal
and PC-PCC areas and medial and inferior frontal re-
gions, which were reported to be vulnerable to the AD
process [19]. PIWIL1 is a member of the PIWI subfamily




Association (Quant.) Cognitive function association
β P Padj Unconditioned Controlling for imaging biomarker (Quant.)
rs429358 (chr19:45411941) Aβ deposition 0.37 2.85 × 10−27 2.89 × 10−24 2.03 × 10−9 0.047
AD-Cm − 0.06 5.61 × 10−6 2.85 × 10−3 2.18 × 10−5
PCC-Cm − 0.10 3.07 × 10−10 3.12 × 10−7 3.16 × 10−3
AD-Ct − 0.11 8.70 × 10−13 8.80 × 10−10 2.82 × 10−3
Hv − 0.78 2.23 × 10−18 2.25 × 10−15 0.150
rs769449 (chr19:45410002) Aβ deposition 0.39 1.51 × 10−25 7.65 × 10−23 7.29 × 10−8 0.260
AD-Cm − 0.06 2.78 × 10−6 2.82 × 10−3 3.08 × 10−3
PCC-Cm − 0.10 8.58 × 10−9 4.36 × 10−6 0.052
AD-Ct − 0.11 2.16 × 10−9 1.09 × 10−6 0.022
Hv − 0.73 3.72 × 10−13 1.88 × 10−10 0.210
rs405509 (chr19:45408836) Aβ deposition − 0.09 5.78 × 10−3 0.84 1.94 × 10−3 0.020
AD-Cm 0.03 3.15 × 10−3 0.40 0.029
PCC-Cm 0.03 0.017 0.83 0.032
AD-Ct 0.02 0.16 0.99 0.011
Hv 0.14 0.089 0.96 0.017
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that plays important roles in stem cell self-renewal, RNA
silencing, translational regulation, and neuron develop-
ment [29], which potentially implicates multiple aspects
of brain degeneration. Moreover, the PIWIL1 variants
also co-localize with a brain-specific H3K27me3 signal
(Supplementary Figure S3b), which may provide insight
into the underlying function of PIWIL1 in neurodegen-
eration of AD-vulnerable regions. Additionally, signifi-
cant associations between common variants in PSEN1
and PSEN2 and neurodegeneration biomarkers of AD
(i.e., PSEN1-rs7523 with AD-Ct and PSEN2-rs75733498
with AD-Cm) were observed. Pathogenic rare variants in
these genes cause early-onset familial AD. These genes
encode major components of the γ-secretase of APP
synthesis and proteolysis, leading to Aβ production [30].
It is not clear how these variants are associated with
AD-type neurodegeneration, but this observation dem-
onstrates that dysregulation of the genes confers suscep-
tibility to AD via alterations of regional cerebral glucose
metabolism or regional cortical thickness, which demon-
strates their versatile roles in AD pathogenesis beyond
altering Aβ production.
Unlike common or rare variants with association, we
found associations between APOE variants and all brain
imaging features of AD. This finding is consistent with
previous reports [31–35], conferring a partial explan-
ation for the genetic link between APOE and AD suscep-
tibility. An association test of a variant in the other LD
block revealed a marginal association, suggesting a spe-
cific functional association between the cell surface re-
ceptor binding region and the imaging features.
Conditional analysis demonstrated a causal relationship
between the imaging features and the association of
APOE variants with AD susceptibility (Table 2).
The gene-level rare variant association test revealed
several genes previously related to AD brain features
with cognitive impairment. Notably, carriers of DSG2
rare variants harbor increased AD-Ct, Hv, and cognitive
function, suggesting that these variants play protective
roles in neurodegeneration in AD-related regions (Fig 4b
and Supplementary Fig. S5a). DSG2 encodes a calcium-
binding glycoprotein components of the desmosome
that binds to plaque proteins and intermediate filaments
[36] and was reported to confer AD risk based on
GWAS [8]. Although a molecular link explaining this as-
sociation remains unclear, we observed that the variants
were located in calcium ion or proteoglycan binding
sites (Supplementary Fig. S5c). These sites are evolution-
ally conserved, and the binding of these molecules is es-
sential for protein function [37].
The KBASE protocol ensures unified subject assessment
and standardization of all samples and data collection,
processing, and quality control. It enables multi-trait ana-
lysis of genetic loci, explicitly targeting each in vivo AD
pathology rather than relying on clinical diagnoses with
limited accuracy.
Strengths and limitations
All individuals enrolled in the KBASE cohort underwent
careful clinical and genetic characterization. The KBASE
protocol adopts unified subject assessment, standardization
of all imaging, biofluid, DNA and RNA data collection, and
processing followed by meticulous data quality control. We
analyzed variants of wide range of allele frequencies on
Fig. 4 Genes with rare variants that are significantly associated with in vivo AD pathologies. Observed rare functional variants in the case or
control groups defined by each clinical parameter are shown for each gene. a LPL with Aβ deposition in the global brain regions. b DSG2 with
AD-signature cortical thickness. c ITPR1 with hippocampal volume. The right panel displays the exploratory voxel-based analyses of brain imaging
to demonstrate the regional pattern differences in AD imaging biomarker phenotype between carriers and non-carriers
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AD-associated genes. Therefore, 132 AD-associated genes
for LOAD were covered for genetic variant associations
with the AD brain imaging features. Our next step will be
to scrutinize the molecular biological mechanisms of vari-
ants and their functions on AD pathology.
Several limitations of our study warrant discussions.
First, we tried to replicate our results using the ADNI
database, which includes unified clinical information,
brain imaging data, and genomic data of participants.
We adjusted raw brain imaging data of ADNI database
using our methodology and conducted association ana-
lyses. However, replication was not feasible due to the
allele frequency differences originated from the ethnic
discrepancies and differences in phenotyping methods,
except the APOE SNVs. We also collected a large-scale
elderly Korean cohort (n = 4683) and conducted a se-
quencing analysis using our customized targeted LOAD
gene panel. Associations between FDG uptake and two
novel SNPs were replicated—rs75733498 on PSEN2 (P =
1.6 × 10−4) and rs2722372 on NME8 (P = 8.6 × 10−3)—al-
though this cohort lacks brain imaging assessment and
cognitive impairment trait was accessible.
Conclusions
Here, we explored the KBASE data and conducted inte-
grative analysis that revealed novel associations between
AD-related gene variants and various brain features.
Thus, scrutinizing the biological mechanisms of genetic
variants and their functions in AD pathology by interro-
gating multiple aspects of brain morphology and in vivo
AD pathologies will lead to a better understanding of
the mechanism of AD pathogenesis.
Supplementary Information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13195-020-00722-2.
Additional file 1. Supplementary methods, tables, and figures.
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